Form 4: Iovance Biotherapeutics CFO Awarded 93,750 Restricted Stock Units

Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, was granted 93,750 restricted stock units (RSUs) on March 5, 2025, which will vest over three years.

Summary

• Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, Inc., was granted 93,750 Restricted Stock Units (RSUs) on March 5, 2025.
• The RSUs represent a contingent right to receive one share of Iovance's common stock each.
• The RSUs will vest over three years, with one-third vesting on the one-year anniversary of the grant date and the remaining RSUs vesting in eight equal quarterly installments over the subsequent two years, provided the reporting person remains employed by the issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued employment with Iovance Biotherapeutics.

Risks

• The value of the RSUs is dependent on the future performance of Iovance's stock price, which is subject to market risks and company-specific factors.
• If the CFO leaves the company before the RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives. The vesting schedule is designed to align management's interests with the long-term success of the company.

Comparison to Industry Standards

• Granting RSUs to key executives is a standard practice in the biotech industry.
• Companies like Gilead Sciences, Amgen, and Biogen also use RSUs as part of their compensation packages.
• The vesting schedule of one-third after one year and the remainder quarterly over the next two years is a fairly typical vesting schedule.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the CFO to drive long-term value.
• Employees may see it as a sign of the company's commitment to its leadership team.

Key Dates